



OptTEST Kick-off Meeting. 2nd Sept 2014
*Jean Monet Building,
EU Commission,
Luxembourg*


***Morning session
(Closed)***

Agenda

Morning (closed session)

- **09.00** Introductions
- **09.10** Work package discussions:
 - WP 4:** Linkage to HIV care*
 - WP 5:** Indicator condition guided HIV testing*
 - WP 6:** Cost-effectiveness of HIV testing strategies*
 - WP 7:** Stigma and legal barriers to HIV testing*
- **11.50** Administration/coordination issues **WP1** (RH)
- **12.15** AOB/close of session
- **12.15 - 12.45** Lunch

Welcome Partners



Co-funded by the 2nd Health Programme of the European Union

Morning session: Objectives

- **Discussions** per WP (45 min each) re:
 - **Detailed work plan:** outlining tasks and steps necessary to reach milestones and deliverables
 - **Evaluation:** determine relevant baseline data, relevant indicators (SMART)
 - Interlinkage between WPs
 - Integration of criminalisation
- **For afternoon**
 - **Stakeholders:** Primary/secondary; How can they be reached/addressed?
 - **Dissemination:** Key messages, tailored to audiences; dissemination of milestones/results

Advisory Board

- Brian West, HIV in Europe Steering committee
- Laura Fernandez (for Jordi Casabona), EURO HIVEDAT
- Eberhard Schatz, Correlation Network
- Dr Lara Tavoschi (for Andrew Amato), ECDC
- Luís Mendão, CSF
- Matthias Wentzlaff-Eggebert, Quality Action
- Martin Donoghoe, WHO Europe
- Jeff Lazarus, HIV in Europe Steering Committee

Consultant on criminalisation

- **Contract made with Lisa Power**

The position was advertised via mailing lists and 6 applications received in August, a committee scored the applications and the successful candidate chosen

Deliverables

- The ‘best-practice toolkit’ to address legal and policy barriers to testing and timely treatment for key groups (Deliverable April, 2017).

Tasks

- Develop a methodology for the data collection and the organisation of the data in the best-practice toolkit;
- Literature review, in collaboration with the leads of “linkage to care” and “indicator condition guided HIV testing”, to identify legal/criminalisation barriers;
- Develop questionnaires and carry out interviews with identified stakeholders;
- Develop a toolkit with evidence, comparative tables, scoreboards and useful resources, amongst others.

Partners involvement and interlinkage WPs

	P 0 Region H	P1 AIDS Fonds	P2 EATG	P3 PHE	P 4 SSAT	P 5 MEDFAS H	P 6 INSERM	P 7 GNP+	P 8 ISCIII	P 9 NIHD
WP 1	WP lead: CHIP									
WP 2	WP lead: CHIP									
WP 3		WP lead: Jorrit Kabel								
WP 4				WP lead: Valerie Delpech						
WP 5					WP lead: Ann Sullivan					
WP 6							WP lead: Yazdan Yazdanpanah			
WP 7								WP lead: Julian Hows		

Countries

Partners

- UK, France, Estonia, Spain

Pilot sites

- Greece, Czech Republic, Poland

WP7 (PLHIV networks)

- Greece, Poland, Estonia, Portugal and Germany

Horizontal work packages 1 - 3

WP 1 Coordination		WP 2 Dissemination	WP 3 Evaluation
WP 4 Linkage to HIV treatment and care	WP 5 Development and implementation of indicator condition guided HIV testing	WP 6 Cost-effectiveness of HIV testing strategies	WP 7 Stigma and legal barriers to HIV testing

WP1-2: Coordination and dissemination

OptTEST for HIE	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12	M13	M14	M15	M16	M17	M18	M19	M20	M21	M22	M23	M24	M25	M26	M27	M28	M29	M30	M31	M32	M33	M34	M35	M36
WP 1 Coordination	J	J	A	S	O	N	D	J	F	M	A	M	J	J	A	S	O	N	D	J	F	M	A	M	J	J	A	S	O	N	D	J	F	M	A	M
Milestone 1: Kick off-meeting																																				
Milestone 2: Year 1 annual meeting and report																																				
Milestone 3: Year 2 annual meeting and report																																				
Milestone 4: Year 3 annual and final meeting and report																																				
Deliverable 1: Interim and final technical and financial report																																				
WP 2 Dissemination of the project	J	J	A	S	O	N	D	J	F	M	A	M	J	J	A	S	O	N	D	J	F	M	A	M	J	J	A	S	O	N	D	J	F	M	A	M
Milestone 1 Stakeholder analysis, communication channels approved																																				
Milestone 2: Construction of OptTEST website																																				
Milestone 3: Promotional leaflet (English, French, Spanish and Russian)																																				
Milestone 4: Press releases/position statements year 1, 2, 3																																				
Milestone 5: Public final project report (English, French, Spanish and Russian)																																				
Deliverable 2: Dissemination Activities																																				

WP 3: Evaluation of the project

	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12	M13	M14	M15	M16	M17	M18	M19	M20	M21	M22	M23	M24	M25	M26	M27	M28	M29	M30	M31	M32	M33	M34	M35	M36
WP 3 Evaluation of the project																																				
Milestone 1: Evaluation methodology developed/approved																																				
Milestone 2: Progress report year 1																																				
Milestone 3: Mid-term evaluation (external)																																				
Milestone 4: Progress report year 2																																				
Milestone 5: Final report																																				
Deliverable 3: Evaluation actions																																				

WP 4: Linkage to and retention in HIV care after diagnosis

OptTEST for HiE	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12	M13	M14	M15	M16	M17	M18	M19	M20	M21	M22	M23	M24	M25	M26	M27	M28	M29	M30	M31	M32	M33	M34	M35	M36
WP 4 Linkage to and retention in HIV care after diagnosis	J	J	A	S	O	N	D	J	F	M	A	M	J	J	A	S	O	N	D	J	F	M	A	M	J	J	A	S	O	N	D	J	F	M	A	M
Specific objective 2: To increase knowledge on linkage to and retention in HIV care after diagnosis across geographical and health care settings and target groups by 2016																																				
Milestone 1: Literature review of current evidence and definitions used to measure link to and retention in HIV care and patient experience, as well as experienced barriers																																				
Milestone 2: Agreed surveillance definitions																																				
Milestone 3: Collation of service data from 7 European countries																																				
Milestone 4: Report of treatment cascade evidence across 7 European countries																																				
Milestone 5: Best practice guidelines																																				
Deliverable 4: Assessment method of treatment cascade																																				

WP 5: Development and implementation of tools and strategies for indicator condition guided HIV testing

OptTEST for HiE	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12	M13	M14	M15	M16	M17	M18	M19	M20	M21	M22	M23	M24	M25	M26	M27	M28	M29	M30	M31	M32	M33	M34	M35	M36
WP 5 Development and implementation of tools and strategies for indicator condition guided HIV testing	J	J	A	S	O	N	D	J	F	M	A	M	J	J	A	S	O	N	D	J	F	M	A	M	J	J	A	S	O	N	D	J	F	M	A	M
Milestone 1: Mapping of current national/regional HIV testing guidelines & best practices																																				
Milestone 2: Implementation of region-specific tools (at least 1 for each of the IC)																																				
Milestone 3: Training modules with competency assessments and certifications available on-line																																				
Milestone 4: Results to contribute to the finalising of Stigma good practice manual																																				
Milestone 5: Publication of findings in peer-reviewed journals																																				
Deliverable 5: Indicator condition guided HIV testing tools and training materials																																				

WP 6: The cost-effectiveness of HIV testing strategies in priority groups and regions

OptTEST for HiE	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12	M13	M14	M15	M16	M17	M18	M19	M20	M21	M22	M23	M24	M25	M26	M27	M28	M29	M30	M31	M32	M33	M34	M35	M36
WP 6 The cost-effectiveness of HIV testing strategies in priority groups and regions	J	J	A	S	O	N	D	J	F	M	A	M	J	J	A	S	O	N	D	J	F	M	A	M	J	J	A	S	O	N	D	J	F	M	A	M
Milestone 1: Documentation of survival benefits, costs, and cost-effectiveness of European HIV testing strategies by region/country																																				
Milestone 2: Development of assessment tool for cost-effectiveness of testing strategies (different settings/epidemics)																																				
Milestone 3: Publication in non-technical language to policy makers, NGOs etc																																				
Milestone 4: Data made available on survival benefits, cost and cost-effectiveness																																				
Milestone 5: Publication in peer-reviewed journal																																				
Deliverable 6: Paper on outcomes, costs, and cost-effectiveness of different HIV testing strategies in different European settings																																				

WP7: Stigma and criminalisation as a barrier to the provision and uptake of HIV testing services

OptTEST for HiE	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12	M13	M14	M15	M16	M17	M18	M19	M20	M21	M22	M23	M24	M25	M26	M27	M28	M29	M30	M31	M32	M33	M34	M35	M36
WP 7 Stigma and criminalisation	J	J	A	S	O	N	D	J	F	M	A	M	J	J	A	S	O	N	D	J	F	M	A	M	J	J	A	S	O	N	D	J	F	M	A	M
Milestone 1: Compilation of data from PLHIV stigma index																																				
Milestone 2: Methodology to document strategies to address HIV related stigma developed and approved; New advocacy resources s Website																																				
Milestone 3: Case studies (25) and completed interviews with key stakeholders on innovative strategies (25)																																				
Milestone 4: Final report on lessons learned on strengthening advocacy, law enforcement sensitisation and improved legal literacy																																				
Milestone 5: Stigma and legal barriers best-practice manual available on OptTEST website																																				
Deliverable 7: Best-practice manual on evidence based interventions to reduce HIV related stigma																																				
Deliverable 8: Best-practice toolkit to facilitate more supportive legal and policy environment																																				

Agenda

Morning (closed session)

- **09.00** Introductions
- **09.10** Work package discussions: *work package brief overview and detailed presentation of the first yearly work plan, including evaluation plan/methodologies to provide enough information to all for further discussions with other Partners*
- **09.10** **WP 4: Linkage to HIV care**
- **09.50** **WP 5: Indicator condition guided HIV testing**
- **10.30** **WP 6: Cost-effectiveness of HIV testing strategies**
- **11.10** **WP 7: Stigma and legal barriers to HIV testing**
- **11.50 Administration/coordination issues (RH)**
- **12.15** AOB/close of session
- **12.15 - 12.45** Lunch

OptTEST: Common reporting deadlines

- **Month 12:**
 - Year 1 annual meeting and report/ work plans to EC
 - Progress report (evaluation)
- **Month 18**
 - Mid-term external evaluation
 - Interim technical and financial report
- **Month 24**
 - Year 2 annual meeting and report/ work plans to EC
 - Progress report year 2 (evaluation)
- **Month 36**
 - Year 3 annual and final meeting and report
 - Final technical and financial report
 - Public final project report (evaluation)

Administration and Finance

	M1	M2	M3	M4	M5	M6	M7	M8	M9	M10	M11	M12
	4th June 2014	July	August				1st Dec 2014					
Payments	EU pay 30% (428,995.20 euros) initial funding	CHIP reimburse all partners <i>after signing of individual contracts</i>										
Reporting to EU (from CHIP)												Annual report
Internal reporting (Partners' to CHIP)			Quarterly reporting on person days, activities and costs			Quarterly reporting on person days, activities and costs			Quarterly reporting on person days, activities and costs			Quarterly reporting on person days, activities and costs

Administration and Finance

- Pre-financing (30%) available now
- 1st further pre-financing (20%)
 - paid when at least 30% of pre-financing is used
 - if less than 70% of pre-financing is used the payment will be reduced by the unused amount
- 2nd further pre-financing (30%)
 - paid when at least 30% of pre-financing is used
 - if less than 70% of pre-financing is used the payment will be reduced by the unused amount
- Balance payment after accepted final report (20%)

Administration and Finance

- Pre-financing by partner

Partner	First installment (30%)	Second installment (20%)	Third installment 30%	Final payment (20%)
UCPH	123.574,46	82.383	123.574,46	82.383
Aids Fonds Netherlands (WP3)	17.083,14	11.389	17.083,14	11.389
EATG (WP1,2,8)	21.450,83	14.301	21.450,83	14.301
PHE (WP4)	48.515,17	32.343	48.515,17	32.343
SSAT/C+W (WP5)	41.211,53	27.474	41.211,53	27.474
MedFASH (WP5)	40.756,60	27.171	40.756,60	27.171
INSERM	57.294,24	38.196	57.294,24	38.196
GNP+ (WP7)	35.612,44	23.742	35.612,44	23.742
Instituto de Salud Carlos III, Madrid, Spain	26.251,82	17.501	26.251,82	17.501
National Institute for Health Development ; Tallinn ; Estonia	17.244,88	11.497	17.244,88	11.497
	428.995,09	285.996,73	428.995,09	285.996,73

Administration and Finance

- **Time sheet** – to be reported to CHIP every 3 months (drop box)

Organisation:	Aids Fonds Netherlands							
Name of the staff:								
Normal working hours per week:	37					Working hours per day:	7,4	
Week starting Monday:								
02-06-2014	Mon	Tue	Wed	Thu	Fri	Sat	Sun	Total hours
WP1 Coordination								0
WP3 Evaluation								0
Total hours	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0
	Proportion of a full week:							0,00
Week starting Monday:								
09-06-2014	Mon	Tue	Wed	Thu	Fri	Sat	Sun	Total hours
WP1 Coordination								0
WP3 Evaluation								0
Total hours	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0

Date:

Date:

Signature of the staff

Signature of the responsible

Days this month per WP

WP1 Coordination	0
WP3 Evaluation	0
Total days this month	0

Administration and Finance

- Budget report** – to be reported to CHIP every 3 months (drop box)

E1. Staff

a. Costs pertaining to public officials: (in-kind contribution from institution)

Acronym of beneficiary organisation	Country Code	Name of person	Function/Category	WP	A Number of days worked for the project	B Daily Rate (€)	A x B Cost (€)
XXXXX	XX	XXXXX XXXXX	XXXXX	1	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX	1	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX	1	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX	1	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX	3	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX	3	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX	3	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX	3	0,00	0,00	0,00
TOTAL							0,00

Need for supporting documentation

Upon request only

b. Costs not pertaining to public officials: (paid by non-institutional funding)

Acronym of beneficiary organisation	Country Code	Name of person	Function/Category		A Number of days worked for the project	B Daily Rate (€)	A x B Cost (€)
XXXXX	XX	XXXXX XXXXX	XXXXX	1	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX	1	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX	1	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX	1	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX	3	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX	3	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX	3	0,00	0,00	0,00
TOTAL							0,00

Upon request only

E2. Travels Costs and subsistences Allowances

a. Travel Costs

Acronym of beneficiary organisation	Country Code	Name of the person travelling	Purpose and dates of the travel	Means of transports	Place of departure (City, Country)	Destination (City, Country)	Cost (€)
XXXXX	XX	XXXXX XXXXX	XXXXX (dd/mm/yyyy)	XXXXXX	XXXXXX, XXXXXX	XXXXXX, XXXXXX	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX (dd/mm/yyyy)	XXXXXX	XXXXXX, XXXXXX	XXXXXX, XXXXXX	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX (dd/mm/yyyy)	XXXXXX	XXXXXX, XXXXXX	XXXXXX, XXXXXX	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX (dd/mm/yyyy)	XXXXXX	XXXXXX, XXXXXX	XXXXXX, XXXXXX	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX (dd/mm/yyyy)	XXXXXX	XXXXXX, XXXXXX	XXXXXX, XXXXXX	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX (dd/mm/yyyy)	XXXXXX	XXXXXX, XXXXXX	XXXXXX, XXXXXX	0,00
TOTAL							0,00

Prior approval for travels outside EU

b. Subsistence Allowances

Acronym of beneficiary organisation	Country Code	Name of the person travelling	Purpose and dates of the travel	Destination (City, Country)	A Number of days	B Cost of the daily allowance	A x B Cost (€)
XXXXX	XX	XXXXX XXXXX	XXXXX (dd/mm/yyyy)	XXXXXX, XXXXXX	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX (dd/mm/yyyy)	XXXXXX, XXXXXX	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX (dd/mm/yyyy)	XXXXXX, XXXXXX	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX (dd/mm/yyyy)	XXXXXX, XXXXXX	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX (dd/mm/yyyy)	XXXXXX, XXXXXX	0,00	0,00	0,00
XXXXX	XX	XXXXX XXXXX	XXXXX (dd/mm/yyyy)	XXXXXX, XXXXXX	0,00	0,00	0,00
TOTAL							0,00

Prior approval for travels outside EU

Administration and Finance

- Q&A
 - Beneficiaries can transfer budget between categories of cost
 - Beneficiaries can transfer budget items to other beneficiaries, but if the overall sum of the budget for a beneficiary is changing due to these transfers, this will require an amendment
 - Cost incurred in other currencies than
 - Euro must be converted using the monthly accounting rate:
http://ec.europa.eu/budget/contracts_grants/info_contracts/inforeuro/inforeuro_en.cfm
 - Deadline for internal reporting (3 monthly): 3 weeks after passing the month.
 - Part time employees; to be hired as consultants? No, consultants are considered subcontractors

Agenda

Morning (closed session)

- **09.10** *WP 4: Linkage to HIV care*
- **09.50** *WP 5: Indicator condition guided HIV testing*
- **10.30** *WP 6: Cost-effectiveness of HIV testing strategies*
- **11.10** *WP 7: Stigma and legal barriers to HIV testing*
- **11.50** Administration/coordination issues (RH)
- **12.15 AOB/close of session**
- **12.15 - 12.45** Lunch



OptTEST Kick-off Meeting. 2nd Sept 2014
*Jean Monet Building,
EU Commission,
Luxembourg*

***Afternoon session
(Open)***

Agenda: Afternoon (open) session

- **12.45** Introduction (RH)
- **13.00** Brief overview of individual work package/work plan presentations
 - **13.00** **WP 4:** Linkage to HIV care
 - **13.30** **WP 5:** Indicator condition guided HIV testing
 - **14.00** **WP 6:** Cost-effectiveness of HIV testing strategies
 - **14.30** **WP 7:** Stigma and legal barriers to HIV testing
- **15.00** Refreshment break
- **15.15** Identify overlaps and linkage with other EU projects/actions
- **15.45** Agree next steps/actions
- **16.00** AOB and close

Background

- Undiagnosed HIV and late presentation for HIV care remains a public health challenge across Europe and novel testing strategies are needed to address this
- The OptTEST project stems from the HIV in Europe initiative, an initiative of clinicians, patient organisations and policy organisation created in 2007 to address how to improve access to testing and care for HIV in Europe
- The workpackages in OptTEST are developed based on outcomes of pilot projects implemented by HIV in Europe partners
- OptTEST will be implemented under the **EU 2nd health programme** having as overall aims to improve health security, reduce health inequalities, disseminate health information & knowledge

Project Objectives

- To develop strategies to improve early diagnosis and care of people with HIV across Europe
- To increase knowledge on linkage to and retention in HIV care after diagnosis across geographical and healthcare settings and target groups (WP4)
- To Implement a novel HIV testing strategy (indicator condition guided HIV testing) in selected European healthcare setting (WP5)
- To assemble and evaluate the cost-effectiveness of various existing HIV testing strategies in Europe (WP6)
- To increase knowledge of how stigma and legal barriers to HIV testing affects the uptake of HIV testing and treatment (WP7)

Main target groups

- Health care professionals and (non) HIV clinicians
- Health care managers and researchers
- Social workers and civil society organization staff
- Policy makers and government officials
- Relevant press/media
- (Undiagnosed) PLHIV and most affected populations

Countries

Partners

- UK, France, Estonia, Spain

Pilot sites

- Greece, Czech Republic, Poland

WP7 (PLHIV networks)

- Greece, Poland, Estonia, Portugal and Germany

Horizontal work packages 1 - 3

WP 1 Coordination		WP 2 Dissemination	WP 3 Evaluation
WP 4 Linkage to HIV treatment and care	WP 5 Development and implementation of indicator condition guided HIV testing	WP 6 Cost-effectiveness of HIV testing strategies	WP 7 Stigma and legal barriers to HIV testing

Afternoon Session Itinerary & Objectives

- **Brief WP presentation to Advisory Board**

(5-10 mins per Work Package)

- **Open discussions with Advisory Board**

(20-25 mins per Work Package)

- *Goals*
- *Stakeholders/Key messages/Dissemination*
- *Evaluation*
- *Synergies with other (EU) projects*

Core Work Packages

Work Package	Lead Partner	Partners	Objective
WP4: Linkage to and retention in HIV care after diagnosis.	PHE	CHIP SSAT INSERM GNP+ ISCIII NIHD	Improve data on linkage to care and observe regional differences by implementing <i>the treatment cascade</i> in different countries, epidemics and health care structures, to present an applicable definition and standard methodology.
WP5: Development and implementation of tools and strategies for indicator condition guided HIV testing.	SSAT	CHIP MEDFASH INSERM ISCIII NIHD	Testing the indicator disease guided HIV testing strategy across Europe and developing applicable tools for broader implementation. Focus will be on barriers on provider level and offer and uptake rates for HIV testing.
WP6: The cost-effectiveness of HIV testing strategies in priority groups and regions.	INSERM	ISCIII NIHD	Determine the cost-effectiveness of different HIV testing strategies in different settings, regions and priority groups in Europe and estimating the survival benefits, cost and cost-effectiveness of innovative HIV testing strategies in Europe.
WP7: Stigma and legal barriers to the provision and uptake of HIV testing services.	GNP+	CHIP PHE	Enable networks of PLHIV to use the data they collect to inform advocacy and build partnerships with health care providers to ensure better and more equitable access to services. Good practice to scale-up testing will be produced and disseminated.

Core Work Packages

Work Package	Lead Partner	Partners	Objective
WP4: Linkage to and retention in HIV care after diagnosis.	PHE	CHIP SSAT INSERM GNP+ ISCIII NIHD	Improve data on linkage to care and observe regional differences by implementing <i>the treatment cascade</i> in different countries, epidemics and health care structures, to present an applicable definition and standard methodology.
WP5: Development and implementation of tools and strategies for indicator condition guided HIV testing.	SSAT	CHIP MEDFASH INSERM ISCIII NIHD	Testing the indicator disease guided HIV testing strategy across Europe and developing applicable tools for broader implementation. Focus will be on barriers on provider level and offer and uptake rates for HIV testing.
WP6: The cost-effectiveness of HIV testing strategies in priority groups and regions.	INSERM	ISCIII NIHD	Determine the cost-effectiveness of different HIV testing strategies in different settings, regions and priority groups in Europe and estimating the survival benefits, cost and cost-effectiveness of innovative HIV testing strategies in Europe.
WP7: Stigma and legal barriers to the provision and uptake of HIV testing services.	GNP+	CHIP PHE	Enable networks of PLHIV to use the data they collect to inform advocacy and build partnerships with health care providers to ensure better and more equitable access to services. Good practice to scale-up testing will be produced and disseminated.

Core Work Packages

Work Package	Lead Partner	Partners	Objective
WP4: Linkage to and retention in HIV care after diagnosis.	PHE	CHIP SSAT INSERM GNP+ ISCIII NIHD	Improve data on linkage to care and observe regional differences by implementing <i>the treatment cascade</i> in different countries, epidemics and health care structures, to present an applicable definition and standard methodology.
WP5: Development and implementation of tools and strategies for indicator condition guided HIV testing.	SSAT	CHIP MEDFASH INSERM ISCIII NIHD	Testing the indicator disease guided HIV testing strategy across Europe and developing applicable tools for broader implementation. Focus will be on barriers on provider level and offer and uptake rates for HIV testing.
WP6: The cost-effectiveness of HIV testing strategies in priority groups and regions.	INSERM	ISCIII NIHD	Determine the cost-effectiveness of different HIV testing strategies in different settings, regions and priority groups in Europe and estimating the survival benefits, cost and cost-effectiveness of innovative HIV testing strategies in Europe.
WP7: Stigma and legal barriers to the provision and uptake of HIV testing services.	GNP+	CHIP PHE	Enable networks of PLHIV to use the data they collect to inform advocacy and build partnerships with health care providers to ensure better and more equitable access to services. Good practice to scale-up testing will be produced and disseminated.

Core Work Packages

Work Package	Lead Partner	Partners	Objective
WP4: Linkage to and retention in HIV care after diagnosis.	PHE	CHIP SSAT INSERM GNP+ ISCIII NIHD	Improve data on linkage to care and observe regional differences by implementing <i>the treatment cascade</i> in different countries, epidemics and health care structures, to present an applicable definition and standard methodology.
WP5: Development and implementation of tools and strategies for indicator condition guided HIV testing.	SSAT	CHIP MEDFASH INSERM ISCIII NIHD	Testing the indicator disease guided HIV testing strategy across Europe and developing applicable tools for broader implementation. Focus will be on barriers on provider level and offer and uptake rates for HIV testing.
WP6: The cost-effectiveness of HIV testing strategies in priority groups and regions.	INSERM	ISCIII NIHD	Determine the cost-effectiveness of different HIV testing strategies in different settings, regions and priority groups in Europe and estimating the survival benefits, cost and cost-effectiveness of innovative HIV testing strategies in Europe.
WP7: Stigma and legal barriers to the provision and uptake of HIV testing services.	GNP+	CHIP PHE	Enable networks of PLHIV to use the data they collect to inform advocacy and build partnerships with health care providers to ensure better and more equitable access to services. Good practice to scale-up testing will be produced and disseminated.



It is still possible to **register** for the **HepHIV 2014 Conference**
Barcelona, 5-7 October 2014

OptTEST meeting
5 October 13:00-15:30
Conference venue: Fira Palace Hotel

Exhibition

Interested parties have the opportunity to exhibit materials.

Contact: Dorthe Raben or conference secretariat: rh-hephiv2014@regionh.dk



Co-funded by the 2nd
Health Programme of
the European Union



OptTEST Kick-off Meeting. 2nd Sept 2014
*Jean Monet Building,
EU Commission,
Luxembourg*

THANK YOU!
& safe trip home